Guidance

2014 shaping up to be bridge year for Lilly

2014 shaping up to be bridge year for Lilly

By

The company's guidance aligns with expectations that 2014 will be a nail-biter.

Putting the big picture ahead of LDL levels

Putting the big picture ahead of LDL levels

By

Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.

Pharma digerati launch advisory firm

Pharma digerati launch advisory firm

By

The duo whose nonprofit served as neutral ground for getting FDA and industry talking about digital marketing is starting a for-profit research and advisory firm.

AMARC Angst: Has FDA put pharma Facebook "Likes" in the crosshairs?

AMARC Angst: Has FDA put pharma Facebook "Likes" in the crosshairs?

What the agency writes in a recent warning letter to a dietary supplement firm is instructive with regard to "Liking" off-label posts.

Company news: MedMira; FDA device ID

Diagnostics firm MedMira gets a contract from the US Army to develop a screening tool, and the FDA proposes some new device guidelines.

How CDC's hep.-C testing advice benefits drugmakers now

By

The CDC's proposal that all US baby boomers get a one-time test for the hepatitis C virus has already given a boost to drugmakers in the antiviral space.

Industry group releases digital best practices

By

Weary of FDA foot-dragging on digital and social media guidance for pharmas, a group of 60-some industry digerati have put together guidelines of their own.

FDA gives guidance on brand, generic names in ads

By

The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.

Email Newsletters